A precise solution to treat cancer.
Over 10 million people are diagnosed with cancer each year. Cancer has been called “the wound that does not heal”. Lumina’s innovative technology targets the wound characteristics of cancer to treat solid tumors and metastases.
Target is absent in healthy tissue but prevalent in nearly all solid tumors.
Target sits outside cells in the extracellular matrix, making it easier to target.
Our lead asset shows reliable uptake across multiple tumor types.
Boston, MA – September 8, 2026 — Lumina Pharmaceuticals, a clinical-stage radiopharmaceutical company, announced today that it has been selected as a showcase company for the 2026–2027 National Cancer Institute Small Business Innovation
Novel, first-in-class radiopharmaceutical targeting a hallmark of the solid tumor microenvironment December 22, 2025, Boston, MA – Lumina Pharmaceuticals, a clinical-stage radiopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA)
